Mirum Pharmaceuticals (MIRM) EPS (Weighted Average and Diluted) (2021 - 2026)
Mirum Pharmaceuticals (MIRM) recorded quarterly EPS (Weighted Average and Diluted) of -$13.43 in Q1 2026, down 11091.67% quarter-over-quarter from -$0.12 in Q4 2025, and down 4376.67% on a YoY basis from $0.31 in Q1 2025.
Mirum Pharmaceuticals (MIRM) EPS (Weighted Average and Diluted) (2021 - 2026) Analysis & Trends
Mirum Pharmaceuticals' EPS (Weighted Average and Diluted) history runs 6 years deep, the most recent figure standing at -$13.43 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) fell 4376.67% year-over-year to -$13.43; the TTM figure through Mar 2026 stood at -$13.62 (down 745.96% YoY), while the FY2025 annual figure was -$0.47, up 74.59% from the prior year.
- EPS (Weighted Average and Diluted) was -$13.43 for Q1 2026 at Mirum Pharmaceuticals, down from -$0.12 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.05 in Q3 2025 to a low of -$13.43 in Q1 2026.
- Historically, EPS (Weighted Average and Diluted) has averaged -$1.4 across 5 years, with a median of -$0.57 in 2023.
- The sharpest annual moves came in 2025 and 2026: EPS (Weighted Average and Diluted) jumped 116.67% in 2025, then sank 4376.67% in 2026.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.99 in 2022, then gained by 27.27% to -$0.72 in 2023, then jumped by 31.94% to -$0.49 in 2024, then surged by 75.51% to -$0.12 in 2025, then sank by 11091.67% to -$13.43 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$13.43 (Q1 2026), -$0.12 (Q4 2025), and $0.05 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Mirum Pharmaceuticals | 6.29 Bn | 5.90 Bn | 131.08 Mn | -13.43 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.43 |
| Dec 31, 2025 | -0.12 |
| Sep 30, 2025 | 0.05 |
| Jun 30, 2025 | -0.12 |
| Mar 31, 2025 | -0.30 |
| Dec 31, 2024 | -0.49 |
| Sep 30, 2024 | -0.30 |
| Jun 30, 2024 | -0.52 |
| Mar 31, 2024 | -0.54 |
| Dec 31, 2023 | -0.72 |
| Sep 30, 2023 | -0.57 |
| Jun 30, 2023 | -1.94 |
| Mar 31, 2023 | -0.80 |
| Dec 31, 2022 | -0.99 |
| Sep 30, 2022 | -1.02 |
| Jun 30, 2022 | -0.84 |
| Mar 31, 2022 | -1.17 |
| Dec 31, 2021 | 1.91 |
| Sep 30, 2021 | -1.55 |
| Jun 30, 2021 | -1.45 |